oesophageal cancer
EMA approves two combination-treatments for an aggressive oesophageal cancer
EMA recommends approval for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a first-line treatment for adults with advanced oesophageal squamous cel...
New Reports Support Improved Cancer Screening Programmes in Europe
Two new reports provide recommendations on digestive cancer screening to the European Commission
...
Heads Up for April! Join us for Oesophageal Cancer Awareness Month
Heads up – please put April in your diaries as Oesophageal Cancer Awareness Month – your support will be greatly appreciated!
...
The EC Approves Nivolumab Plus Chemotherapy as First Line Treatment for Oesophageal Cancer
European Commission approves nivolumab plus chemotherapy as first line treatment for oesophageal cancer
...
Nivolumab prolongs disease-free survival in patients with resected oesophageal cancer
New study shows nivolumab prolongs disease-free survival in patients with resected oesophageal cancer
...
April is Oesophageal Cancer Awareness Month
Digestive Cancers Europe is pleased to offer resources to help raise awareness on this cancer that is hard to diagnose and treat
...
First Immunotherapy Drug Approval in Europe for Patients with Oesophageal Squamous Cell Carcinoma
Discover this promising news as it is the first treatment of its kind for these patients
...
Study Shows Blood Test Promising for Targeting of Some Cancer Treatments – DiCE Lends its Voice
Discover this promising advance for stomach and oesophageal cancer patients
...